Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor

  • S. A. Eccles
  • H. Modjtahedi
  • W. Court
  • J. Titley
  • G. Box
  • C. Dean
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 19)


There is abundant evidence to suggest that over-expression of growth factor receptors and/or autocrine production of one or more ligands may provide tumour cells with significant advantages in growth and dissemination. One clinically important group is that of the c-erbB family of type 1 receptor tyrosine kinases exemplified by epidermal growth factor receptor (EGFR; reviewed by Harris et al. 1992; Khazaie et al. 1993; Modjtahedi and Dean 1994; Baselga and Mendelsohn 1994; Eccles et al. 1995). The cell surface location of these molecules renders them attractive targets for a variety of immunotherapeutic strategies, some of which are showing promise in preclinical and early clinical trials.


Epidermal Growth Factor Receptor Athymic Mouse Human Tumour Xenograft A549 Lung Adenocarcinoma Cell Therapeutic Mabs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (1988) Efficacy of antibodies to epidermal growth factor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605–1611PubMedCrossRefGoogle Scholar
  2. Baselga J, Mendelsohn J (1994) The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127–138PubMedCrossRefGoogle Scholar
  3. Dean C, Modjtahedi H, Eccles S, Box G, Styles J (1994) Immunotherapy with antibodies to the EGF receptor. Int J Cancer [Suppl] 8:103–107CrossRefGoogle Scholar
  4. Eccles S, Box G, Court W, Sandle J, Dean CJ (1994) Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 24/25:279–291PubMedGoogle Scholar
  5. Eccles S, Modjtahedi H, Box G, Court W, Sandle J, Dean C (1995) Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14:337–348Google Scholar
  6. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J (1992) Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 11:181–188PubMedGoogle Scholar
  7. Khaziae K, Schirrmacher V, Lichtner RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255–274CrossRefGoogle Scholar
  8. Masui H, Moroyama T, Mendelsohn J (1986) Mechanism of antitumour activity in mice for anti-epidermal growth factor antibodies with different isotypes. Cancer Res 46:5592–5598PubMedGoogle Scholar
  9. Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4:227–296Google Scholar
  10. Modjtahedi H, Dean C (1995a) Antibody-induced inhibition of EGFR overexpressing tumours occurs in the absence of receptor down-regulation. Int J Oncol 7:783–788PubMedGoogle Scholar
  11. Modjtahedi H, Dean C (1995b) The binding of HB-EGF to tumour cells is blocked by mabs which act as EGF and TGFα antagonists. Biochem Biophys Res Commun 207:389–397PubMedCrossRefGoogle Scholar
  12. Modjtahedi H, Styles J, Dean CJ (1993a) The growth response of human tumour cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int J Oncol 3:237–243PubMedGoogle Scholar
  13. Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B, Dean C (1993b) Antitumour activity of rat Mabs to the human receptor for EGF. In: Epenetos AA, Lemoine NR (eds) Mutant oncogenes: targets for therapy? Chapman and Hall, London, p 35Google Scholar
  14. Modjtahedi H, Styles JM, Dean CJ (1993c) The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on breast carcinoma MDA-MB 468. Br J Cancer 67:247–253PubMedCrossRefGoogle Scholar
  15. Modjtahedi H, Eccles S, Box G, Styles J, Dean C (1993d) Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67:254–261PubMedCrossRefGoogle Scholar
  16. Modjtahedi H, Eccles SA, Box G, Styles J, Dean CJ (1993e) Antitumor activity of combinations of antibodies directed against different epitopes on the extacellular domain of the human EGF receptor. Cell Biophys 22:129–146PubMedGoogle Scholar
  17. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J Dean C (1994) Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54:1695–1701PubMedGoogle Scholar
  18. Modjtahedi H, Jackson E, Dean C (1995) Monovalent antibodies to the epidermal growth factor (EGF) receptor: effects on proliferation and differentiation of tumors overexpressing the EGF receptor. Tumor Target 1:99–106Google Scholar
  19. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M (1996) Phase 1 trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 73:228–235PubMedCrossRefGoogle Scholar
  20. Nair S, Mayotte J, Lockshin A, Levitt M (1994) Induction of squamous differentiation by interferonβ in a human non-small cell lung cancer cell line. J Natl Cancer Inst 86:378–383PubMedCrossRefGoogle Scholar
  21. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller B (1993) Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37:343–349PubMedCrossRefGoogle Scholar
  22. Radinsky R (1995) Molecular mechanisms for organ-specific colon carcinoma metastasis. Eur J Cancer 31A:1091–1095PubMedCrossRefGoogle Scholar
  23. Rodeck U, Herlyn, M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 47:3692–3696PubMedGoogle Scholar
  24. Sato JD, Le AD, Kawamoto T (1987) Derivation and assay of biological effects of monoclonal antibodies to epidermal growth factor receptors. Methods Enzymol 146:63–81PubMedCrossRefGoogle Scholar
  25. Wikstrand C, Hale LP, Batra SK et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140–3148PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • S. A. Eccles
  • H. Modjtahedi
  • W. Court
  • J. Titley
  • G. Box
  • C. Dean

There are no affiliations available

Personalised recommendations